{
    "nctId": "NCT03272919",
    "briefTitle": "Chemotherapy Induced Peripheral Neuropathy (CIPN)",
    "officialTitle": "Chemotherapy Induced Peripheral Neuropathy (CIPN): A Pilot Study of Intraneural Facilitation for Managing Chemotherapy-Induced Peripheral Neuropathy",
    "overallStatus": "COMPLETED",
    "conditions": "Chemotherapy-induced Peripheral Neuropathy",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 44,
    "primaryOutcomeMeasure": "Descriptive Statistics to measure the degree of peripheral neuropathy in the two arms based on the PQAS score.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Newly diagnosed stages I to III breast cancer patients with any biomarker status (ER, PR and HER) receiving treatment with platinum-based compounds (Carboplatin and Cisplatin) and/or taxanes (Docetaxel and Paclitaxel).\n* Chemotherapy naive patients with gynecologic cancers including ovarian, uterine, and cervical cancer planning to receive definitive number of platinum-based compounds (carboplatin or cisplatin) and/or taxanes (docetaxel and paclitaxel) chemotherapy.\n* Planned to receive a minimum of 4 cycles of treatment with either of the offending chemotherapy agents (a cycle of weekly paclitaxel is considered 3 doses).\n* Women aged \u2265 18 years at signing of informed consent\n* No pre-existing peripheral neuropathy (WPPN)\n* ECOG status 0 or 1\n* Able to provide written, informed consent to participate in the study and follow the study procedures.\n* Cannot participate in another non-medical intervention/therapy for peripheral neuropathy\n* Cannot receive more than 3 weeks of treatment with implicating chemotherapy prior to start of study assigned therapy.\n\nExclusion Criteria:\n\n* Male\n* Preexisting peripheral neuropathy.\n* Previous exposure to any of the implicated chemotherapy agents within the last 5 years (platinum-based compounds, vinca alkaloids and/or taxanes) that could potentially cause peripheral neuropathy\n* Evidence of significant medical illness, or psychiatric illness/social situation that would, in the investigator's judgment, make the patient inappropriate for this study.\n* Stage IV or metastatic breast cancer\n* Any physical or neurological disability that would preclude patients from participating in physical therapy",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}